Purpose: To determine the relationship between pregnancy-associated plasma protein-A (PAPP-A) levels and uterine Doppler ultrasonography for the prediction of severe preeclampsia (PE) and HELLP syndrome at the last trimester. Methods: Two groups were constructed; severe preeclampsia group consisted of 38 women; HELLP Syndrome group consisted of 12 women. Both groups were matched strictly for gestational age at last trimester. Maternal blood sample for PAPP-A was collected and uterine Doppler ultrasonography was performed as soon as any woman under the study was diagnosed as severe preeclampsia or HELLP syndrome at last trimester and compared. Results: Mean ages of participants, Parity, gestational weeks and fetal weights were similar. Mean PAPP-A levels were significantly higher in severe preeclampsia and HELLP groups. There was a statistically significant difference regarding Resistive Index (RI) (P<0.001) and Pulsatility Index (PI) (P=0.005) between cases presenting with severe preeclampsia and HELLP groups. Conclusion: PAPP-A levels could provide prediction for severe preeclampsia and HELLP syndrome at last trimester. Increased uterine artery resistance in the third trimester of pregnancy could be used to predict maternal complications including severe preeclampsia and HELLP syndrome.
INTRODUCTION
HELLP was first described by Weinstein in 1982. The acronym is for haemolysis (H), elevated liver enzymes (EL), thrombocytopenia (low platelet count LP). The name of the syndrome (hell + help) suggests the severity of maternal and fetal prognosis. It occurs in 0.17-0.85% of all pregnancies, and is more frequent in older multiparous Caucasian women. In 70% of the cases, the disorder is diagnosed antepartum: 10% before 27 weeks of gestation (WG), 70% between 27-37 WG, 20% after 37 WG. In 30% of cases it is diagnosed postpartum since it has a poor prognosis (Siabi, 2004) .
HELLP syndrome is a multisystemic disorder, whose etiopathogenesis is not completely understood. The most widely accepted hypotheses are: a change in the immune feto-maternal balance, platelet aggregation, endothelial dysfunction, arterial hypertension and an inborn error of the fatty acid oxidative metabolism. Hepatic involvement occurs by intravascular fibrin deposition and hypovolemia. Materno-fetal complications cause a 6.7-70% perinatal mortality rate and a 1-24% maternal mortality rate. The recognition of HELLP syndrome and the rapid initiation of therapy are required for the improvement of materno-fetal prognosis (Holub et al., 2005) .
Preeclampsia, which affects about 3 to 5% of pregnant women, is the most frequent medical complication in pregnancy and the most important cause of maternal and perinatal morbidity and mortality. During the past three decades, numerous clinical, biophysical, and biochemical screening tests have been proposed for the early detection of preeclampsia. Literature shows large discrepancies in the sensitivity and predictive value of several of these tests. Al-Bokhary, et al Vol. 36, No.1, Dec. 2016 57 No single screening test used for preeclampsia prediction has gained widespread acceptance into clinical practice. Instead, its value seems to be in increasing the predictive value of panels of tests, which include other clinical measurements (Hulstein et al., 2006) .
Pregnancy-associated placental protein A (PAPP-A) is a large and highly glycosylated protein, which is produced by the developing trophoblast.
PAPP-A modulates the activity of insulin-like growth factors by cleaving insulin-like growth factor binding proteins. It is proposed to play a role in implantation and is used as a biomarker for Down's syndrome. In chromosomally normal early pregnancies, there is evidence that low maternal serum PAPP-A is associated with an increased risk of subsequently developing PE. However, measurement of PAPP-A is not an effective stand alone screening tool for PE, because less than 20% of the affected cases present serum levels below the fifth centile (Gagnon et al., 2008) .
Poor placentation with deficient remodeling of the spiral arteries has been associated with subsequent development of the early-onset forms of PE, Intra-Uterine Growth Restriction (IUGR), and other associated complications.
In these abnormal pregnancies, the uteroplacental circulation remains in a state of high resistance, which can be measured noninvasively by uterine artery Doppler ultrasound. The impedance is increased in early PE and IUGR and predates the onset of the clinical symptoms by several weeks (Miller et al., 2008) .
A number of studies examined the effectiveness of uterine artery Doppler in predicting the complications associated with impaired placentation. Early reports used subjective qualitative assessment evaluating the presence of a diastolic notch. However, in the last ten years, the use of continuous variables has achieved widespread acceptance as they provide more objective measurements to quantify the vascular impedance. Specifically, the mean pulsatility index (PI) has been studied as an objective measurement, and normal ranges from 11 to 41 weeks have been published (Gomez et al., 2008) .
The aim of this study was to examine the combination of uterine artery Doppler study, together with PAPP-A measurement for the early prediction of the HELLP syndrome (L.M.P.). If this differed from the ultrasound estimate by more than 7 days, the ultrasound estimate was used. All participants signed an informed consent.
MATERIALS AND METHODS

This
If hemolysis or elevated liver enzymes or a low platelet count was determined, patients were diagnosed as HELLP syndrome. The quantitative determination of PAPP-A in the maternal serum was performed with an Immulita/Immulite 1000 device using solid phase, chemiluminescence immunometric sandwich method. Blood samples were centrifugated as soon as they were taken; they were not stored in deep freeze and studied as soon as possible. 
Statistical analysis:
RESULTS
Mean gestational ages of the severe PE and HELLP groups were 31.48
±3.17 and 31.2±2.28 respectively. Demographic properties and estimated fetal weights by ultrasonography of the groups were similar (Table 1) . Mean 24 hours urinary protein excretion of group 1 was higher than group 2. Mean blood pressures (both systolic and diastolic) of the groups were not significantly different (Table 1) . Mean PAPP-A levels were significantly higher in severe preeclampsia and HELLP groups than normal levels (normal level of PAPP-A: 2819 miu/L "1.00 MoM"). PAPP-A levels
were not different when severe preeclampsia was compared with the group of HELLP syndrome (Table 1) . There was a significantly positive and strong correlation between the gestational age and PAPP-A levels and also between fetal weight and PAPP-A levels (correlation coefficents = 0.83 and 0.78, respectively). Mean time interval between PAPP-A assessment and delivery was 3.51 ± 2.15 days in severe-preeclampsia and 1.6 ± 1.22 days in HELLP syndrome.
There was no significant correlation between PAPP-A levels and delivery time for both groups (correlation coefficent = 0.34) ( Table 2) . While in the HELLP syndrome group (n=12); bilateral early diastolic notch was found in 8 cases (66.6%). In an another 2 patients (16.7%), it was found unilaterally, while in the last 2 patients (16.7%), early diastolic notch was not found in either of the uterine arteries (Table 5 ; Figure 3 ). 
DISCUSSION
The etiology of preeclampsia is still unknown but it is now clear that this condition is characterized by poor implantation and development of the trophoblast in the maternal decidua (Davison et al., 2004) . However, although the diagnosis of severe preeclampsia is readily achievable by current clinical assessments, clinicians are awaiting the development of biomarkers that can be used during the early phases of apparently uncomplicated pregnancy to predict the subsequent development of preeclampsia. To date, several proteins that are elevated in the maternal sera, including activin A/ inhibin A (Canini et al., 2008) , leptin (Davison et al., 2004) More recent studies have shown that reduced first trimester serum levels of PAPP-A are associated with subsequent preeclampsia (Davison et al., 2004) . It has been suggested that PAPP-A is useful as a marker of fetal growth restriction at the first trimester (Davison et al., 2004 ) but there are not many studies concerning late pregnancy levels of PAPP-A at preeclampsia.
PAPP-A was first shown to be elevated in the plasma of preeclamptic women nearly 30 years ago. It was showed that elevated levels in severe preeclampsia were detected within 24 hours of admission to hospital but PAPP-A values in mild-preeclampsia did not differ significantly from the normal value for the corresponding stage of gestation (Nishizawa et al., 2008) . Some of the later studies confirmed this post onset elevation of serum PAPP-A (Davison et al., 2004) . But some other studies reported that there is no correlation of PAPP-A in preeclampsia but PAPP-A2 instead (Deveci et al., 2009) . Uncertainty of specificity of the anti-PAPP-A antibodies possibly underlies this discrepancy. PAPP-A2 was the first protein identified as having a similar structure to PAPP-A (Davison et al., 2004) . Both PAPP-A and -A2 are involved in the IGF pathway. PAPP-A is a protease that cleaves IGFbinding protein IGFBP4 and IGFBP5, leading to the activation of IGF-I and II, whereas PAPP-A2 has been reported to cleave only IGFBP5 (Davison et al., 2004) . Both enzymes are expressed in a wide range of tissues, but abundantly in placental syncytiotrophoblasts and the pregnant uterus. Nishizawa et al. (2008) reported that instead of PAPP-A, PAPP-A2 increased in placenta of preeclamptic women compared to uncomplicated pregnancy by western blot and quantitative RT-PCR analysis. They also found that, serum PAPP-A2 levels were detected at significantly higher levels in patients with preeclampsia, the pre-eclampsia cut off value of 39.32 ng/µl allowed for both high sensitivity (95.0%) and high specificity (85.7%).
However, the serum concentrations of PAPP-A did not correlate well with the presence of preeclampsia. Bersinger et al. (2003) have measured the concentrations of PAPP-A in placental extracts to specifically study the changes in the placenta in preeclampsia as serum levels reflect cumulative changes in all potential sources. They found that the placental content reflected the serum pattern for PAPP-A in preeclampsia, suggesting that the placenta is a source of the elevated circulating proteins in preeclampsia.
Our study is consistent with Bersingefls and Deveci's studies that PAPP-A at last trimester significantly increases in severe preeclampsia and HELLP syndrome (Davison et al., 2004) . Deveci et al. (2009) The level of blood pressure is only one of the factors representing the severity of preeclampsia. After the cut off value of 160/1l0 mmHg which discriminates the mild and severe preeclampsia, there is no enough finding to conclude that more increase in blood pressure means more severe the disease Al-Bokhary, et al Vol. 36, No.1, Dec. 2016 69 (Canini et al., 2008) .That is why, instead of performing correlation analysis between mean blood pressure with PAPP-A levels, we preferred grouping the women as severe preeclampsia and HELLP syndrome according to classical worldwide criteria. We found that PAPP-A at last trimester increased in both severe preeclampsia and HELLP syndrome and there was no significant difference in PAPP-A levels between the two groups which indicate that PAPP-A level is not related to severity of the disease.
Mean uterine artery Doppler measurements (pulsatility and resistance indices) found in the women evaluated in this study (1.37 and 0.60, respectively) may be considered high, as some investigators consider pulsatility indices (PI) > 1.20 and resistance indices (RI) > 0.58 as resistant . This result may be explained by the fact that only women in whom diagnosis of preeclampsia had already been defined were included in this study. With respect to the frequency of persistence of early diastolic notch, bilateral in 60% of cases, unilateral in 24% and both bilateral and unilateral in 84%, these values are higher than those reported in a study carried out in the third trimester of pregnancy in patients with preeclampsia in which the frequency of persistence of early diastolic notch was reported as 35% (Li et al., 2005) . These findings suggest a significant vasospastic pattern in the women in this study that may be explained by the strictness of the admission criteria adopted for participation in the trial.
With respect to the evaluation of the biological characteristics (age and BMI) of the patients enrolled in the present study, the results found were similar to those reported in other studies carried out in the northeast of Brazil (Melo et al., 2007) ; however, the mean age of 26 years of patients in the With respect to BMI, the mean of 27.8 kg/m2 found in this study is high and indicative of overweight, and is similar to other reports on patients with preeclampsia (Plasencia et al., 2007 , Papageorghiou et al., 2005 . There was no statistically significant difference between the groups with respect to age, parity or BMI. Therefore, the characteristics of the majority of primiparous patients with a tendency towards overweight found in the present study are similar to the profile observed in patients with a greater risk for preeclampsia in pregnancy (Duckitt et al., 2005) .
The present study also has certain limitations. Collection of serum for PAPP-A for every gestational week for every patient may be considered as a first limitation of the study because it is known that PAPP-A levels increase throughout the pregnancy so the groups must be strictly age matched.
Another limitation is relatively small number of participants especially for HELLP group. Further studies involving large samples at last trimester are needed.
CONCLUSION
The results of this study provide further support to the hypothesis that PAPP-A levels at late pregnancy increase in severe preeclampsia and HELLP syndrome. A cutoff level could be useful for differentiating normal pregnancy Al-Bokhary, et al Vol. 36, No.1, Dec. 2016 71 from preeclampsia. The level of PAPP-A is strongly correlated with fetal birth weight and gestational age but not associated with severity of the disease.
The 
RECOMMENDATION
It is possible that future studies with an adequate sample size will show statistically significant differences with respect to the frequency of these outcomes.
There is a clear need to increase the number of studies in this area given the growing literature relating hypertensive disorders of pregnancy to future cardiovascular disease. For a more precise evaluation of this association, knowledge on the clinical evolution of these patients in the puerperium is essential. 
